Tag Archives: Date March

Business, Finance, Occupation & Industry

Media Advisory: Norsat to Host Media Event

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Media Advisory: Norsat to Host Media Event


Government of Canada to Invest in Innovative Communication Solutions

VANCOUVER, British Columbia–(BUSINESS WIRE)– Norsat International Inc. (“Norsat” or “the Company”) (TSX: NII and OTC BB: NSATF), a leading provider of innovative communication solutions that enable the transmission of data, audio and video for challenging applications and environments announces that the Honourable Kerry-Lynne Findlay, Member of Parliament (Delta-Richmond East) and Associate Minister of National Defence, will announce a contribution under the Strategic Aerospace and Defence Initiative.

A media event to mark the contribution will be held and details are below.

…read more
Source: FULL ARTICLE at DailyFinance

Date:

    March 28, 2013

Time:

1:00 PM
Business, Finance, Occupation & Industry

RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extens

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RYTARY TM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data to be Presented at the American Academy of Neurology Conference

HAYWARD, Calif.–(BUSINESS WIRE)– Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NAS: IPXL) , today announced that data from the RYTARYTM Phase III and open-label extension trials will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California, held from March 16 to March 23. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s disease.

The presentation of IPX066 posters is as follows:

Date: March 18, 2013 (all posters)
Time: 2:00-6:30, with authors in attendance from 5:30-6:30 PM PT (all posters)
Location: San Diego Convention Center

Presentation Title and Number:
Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules
in Patients with Motor Fluctuations in Advanced Parkinson’s Disease
Abstract / Poster Number: 3706/ P01.065

Presentation Title and Number:
Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules
in Patients with Early Parkinson’s Disease
Abstract / Poster Number: 3662/ P01.064

Presentation Title and Number:
Analysis of IPX066 Dosing Data in Advanced Parkinson’s Disease (PD) Patients
Abstract / Poster Number: 49/ P01.063

About RYTARY TM (IPX066)

RYTARY is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s disease. It is not approved or licensed anywhere in the world. Results from the phase III studies of RYTARY, APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) have previously been announced.

On January 21, 2013, Impax received a complete response letter which indicated that the FDA could not approve the NDA at that time. The complete response letter stated that satisfactory resolution and verification of the deficiencies identified during the inspection of the manufacturing facility in …read more
Source: FULL ARTICLE at DailyFinance